

37. The method according to claim 34, wherein said antibodies bind to tetratriacontagastrin G34.

38. The method according to claim 34, wherein said antibodies comprise a mixture of antibodies that bind to heptadecagastrin G17 and antibodies that bind to tetratriacontagastrin G34.

39. The method according to claim 30, wherein said agent is selected from the group consisting of a histamine H₂ receptor blocker and a proton pump inhibitor.

40. The method according to claim 39, wherein said blocker is selected from the group consisting of ranitidine, cimetidine, famotidine, and nizatidine.

41. The method according to claim 39, wherein said inhibitor is selected from the group consisting of omeprazole, lansoprazole and pantoprazole.

42. The method according to claim 30, wherein said mammal is administered said immunogenic composition before said agent.

43. The method according to claim 30, wherein said composition and agent are co-administered to said mammal.

REMARKS

Upon entry of this preliminary amendment, the claims pending are claims 7 and 15-43. New claims 15-43 are supported throughout the specification and by original claims 1-14.

Specification pages 18, 20 and 21 are amended to insert SEQ ID NOS.

The attached Abstract of the Disclosure is supported throughout the specification.

No new matter is introduced by this preliminary amendment and Applicants respectfully request consideration of the pending claims.

A check in the amount of \$90.00 covering the extra claim fees is attached herewith. The Director of the U. S. Patent and Trademark Office is hereby authorized to charge any deficiency in any fees due with the filing of this paper or credit any overpayment in any fees to our Deposit Account No. 08-3040.

Respectfully submitted,

HOWSON AND HOWSON
Attorneys for Applicant

By Mary E. Bak
Mary E. Bak
Registration No. 31,215
Spring House Corporate Center
Box 457
Spring House, PA 19477
(215) 540-9200